Skip to main content
. 2021 Apr 25;23(10):1612–1676. doi: 10.1093/europace/euab065

Secondary prevention of atherothrombotic events in patients with chronic coronary syndrome and/or symptomatic peripheral artery disease patients without AF (i.e. no OAC indication)

Standard dose Comments/dose reduction
Rivaroxaban516 2.5 mg BID In addition to aspirin

AF, atrial fibrillation; BID, twice daily; OAC, oral anticoagulation.